Functional dissection of the retrograde Shiga toxin trafficking inhibitor Retro-2

The retrograde transport inhibitor Retro-2 has a protective effect on cells and in mice against Shiga-like toxins and ricin. Retro-2 causes toxin accumulation in early endosomes and relocalization of the Golgi SNARE protein syntaxin-5 to the endoplasmic reticulum. The molecular mechanisms by which t...

Full description

Saved in:
Bibliographic Details
Published in:Nature chemical biology Vol. 16; no. 3; pp. 327 - 336
Main Authors: Forrester, Alison, Rathjen, Stefan J., Daniela Garcia-Castillo, Maria, Bachert, Collin, Couhert, Audrey, Tepshi, Livia, Pichard, Sylvain, Martinez, Jennifer, Munier, Mathilde, Sierocki, Raphael, Renard, Henri-François, Augusto Valades-Cruz, César, Dingli, Florent, Loew, Damarys, Lamaze, Christophe, Cintrat, Jean-Christophe, Linstedt, Adam D., Gillet, Daniel, Barbier, Julien, Johannes, Ludger
Format: Journal Article
Language:English
Published: New York Nature Publishing Group US 01-03-2020
Nature Publishing Group
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The retrograde transport inhibitor Retro-2 has a protective effect on cells and in mice against Shiga-like toxins and ricin. Retro-2 causes toxin accumulation in early endosomes and relocalization of the Golgi SNARE protein syntaxin-5 to the endoplasmic reticulum. The molecular mechanisms by which this is achieved remain unknown. Here, we show that Retro-2 targets the endoplasmic reticulum exit site component Sec16A, affecting anterograde transport of syntaxin-5 from the endoplasmic reticulum to the Golgi. The formation of canonical SNARE complexes involving syntaxin-5 is not affected in Retro-2-treated cells. By contrast, the interaction of syntaxin-5 with a newly discovered binding partner, the retrograde trafficking chaperone GPP130, is abolished, and we show that GPP130 must indeed bind to syntaxin-5 to drive Shiga toxin transport from the endosomes to the Golgi. We therefore identify Sec16A as a druggable target and provide evidence for a non-SNARE function for syntaxin-5 in interaction with GPP130. The ER exit site component Sec16A was identified as the target of Retro-2, a small-molecule inhibitor of protein toxins and pathogens. Retro-2 treatment alters retrograde early/maturing endosomes-to-Golgi trafficking of Shiga toxin.
Bibliography:PMCID: PMC7039708
ISSN:1552-4450
1552-4469
DOI:10.1038/s41589-020-0474-4